Eloxx Pharmaceuticals, Inc.
ELOX
$16.57
$0.402.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -- | 10.33M | 11.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 28.95M | 34.42M |
| Operating Income | -- | -- | -- | -28.95M | -34.42M |
| Income Before Tax | -- | -- | -- | -30.68M | -36.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | -30.68 | -36.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -30.68M | -36.07M |
| EBIT | -- | -- | -- | -28.95M | -34.42M |
| EBITDA | -- | -- | -- | -28.88M | -34.34M |
| EPS Basic | -- | -- | -- | -14.16 | -16.65 |
| Normalized Basic EPS | -- | -- | -- | -8.73 | -10.41 |
| EPS Diluted | -- | -- | -- | -14.17 | -16.65 |
| Normalized Diluted EPS | -- | -- | -- | -8.73 | -10.41 |
| Average Basic Shares Outstanding | -- | -- | -- | 8.67M | 8.67M |
| Average Diluted Shares Outstanding | -- | -- | -- | 8.67M | 8.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |